标签归档：catenin

KY1220

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

KY1220  纯度: ≥98.0%

KY1220作用于 Wnt/β-catenin 靶点，使β-catenin 和 Ras不稳定。在HEK293报告细胞中的IC50 值为2.1 μM。

KY1220

KY1220 Chemical Structure

CAS No. : 292168-79-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1380 In-stock
2 mg ￥800 In-stock
5 mg ￥1500 In-stock
10 mg ￥2500 In-stock
25 mg ￥5500 In-stock
50 mg ￥9400 In-stock
100 mg ￥16000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

KY1220 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Transcription Factor Targeted Library

生物活性

KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC50 of 2.1 μM in HEK293 reporter cells.

IC50 & Target

IC50: 2.1 μM (HEK293 reporter cells)[1]
体外研究
(In Vitro)

KY1220 shows an IC50 of 2.1 μM in HEK293 reporter cells. KY1220 dose dependently decreases Wnt3a-CM-induced TOPflash reporter activation and mRNA expression of Wnt target genes CCND1 and MYC in HEK293 cells. In HEK293 cells, both β-catenin and panRas protein levels are similarly reduced in a dose-dependent manner after treatment with KY1220, whereas the mRNA levels of CTNNB1 (which encodes β-catenin), NRAS, KRAS and HRAS remain unchanged. K-Ras, which has a critical role in progression of CRCs, is also destabilized by KY1220 via polyubiquitin-dependent proteasomal degradation. KY1220 accelerates the degradation rates of both β-catenin and Ras in SW480 cell lines. Ras destabilization by KY1220 consequently inhibits the activities of both ERK and Akt, which are downstream effectors of Ras in SW480 cells harboring a KRAS mutation. The proliferation and transformation of the HCT15, SW480, D-WT and D-MT CRC cells are efficiently inhibited after treatment with KY1220[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

314.32

Formula

C14H10N4O3S
CAS 号

292168-79-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (318.15 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1815 mL 15.9074 mL 31.8147 mL
5 mM 0.6363 mL 3.1815 mL 6.3629 mL
10 mM 0.3181 mL 1.5907 mL 3.1815 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Cha PH, et al. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation. Nat Chem Biol. 2016 Aug;12(8):593-600.
Cell Assay
[1]

HCT15 or SW480 cells are treated with 25 μM KY1220 or KYA1797K or with control (DMSO) for 72 h. Cell proliferation is measured using the MTT assay. The absorbance of the formazan product is determined at 590 nm every 24 h[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Cha PH, et al. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation. Nat Chem Biol. 2016 Aug;12(8):593-600.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CWP232228

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

CWP232228  纯度: 98.31%

CWP232228 是一种高效的选择性 Wnt/β-catenin 信号通路抑制剂，在细胞核中，拮抗 β-catenin 与 T 细胞因子 (TCF) 结合。CWP232228 通过抑制乳腺癌和肝癌干细胞 (CSCs) 的生长来抑制肿瘤的形成和转移而无毒性。

CWP232228

CWP232228 Chemical Structure

CAS No. : 1144044-02-9

规格 价格 是否有货 数量
5 mg ￥6000 In-stock
10 mg ￥9000 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

CWP232228 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs)[1].

IC50 & Target

Wnt/β-catenin[1]
体外研究
(In Vitro)

CWP232228 (0.01-100 μM; 48 hours) inhibits cell proliferation with IC50 values are 2 and 0.8 μM in mouse (4T1) and human (MDA-MB-435) breast cancer cell lines, respectively[1].
CWP232228 (0.01-10 μM; 48 hours) inhibits cell proliferation with IC50s of 2.566, 2.630, and 2.596 μM in Hep3B, Huh7 and HepG2 cells, respectively[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: Mouse (4T1) and human (MDA-MB-435) breast cancer cell lines
Concentration: 0.01, 0.1, 1, 10, 100 μM
Incubation Time: 48 hours
Result: IC50s were 2 and 0.8 μM for 4T1 and MDA-MB-435 cell lines, respectively.

Cell Proliferation Assay[2]

Cell Line: Hepatocellular carcinoma cell lines HepG2, Huh7, and Hep3B
Concentration: 0.01, 0.1, 0.5, 1, 5, 10 μM
Incubation Time: 48 hours
Result: IC50s were 2.566, 2.630, and 2.596 μM for Hep3B, Huh7 and HepG2 cells, respectively.

体内研究
(In Vivo)

CWP232228 (100 mg/kg, administered i.p.; daily; 21days for mice bearing 4T1 cell tumors; 60 days for mice bearing MDA-MB-435 cell tumors) results in a significant reduction in tumor volume[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 7-week-old female Balb/c and NOD/SCID mice bearing 4T1 or MDA-MB-435 cell tumors[1]
Dosage: 100 mg/kg
Administration: Administered i.p.; daily; 21days for mice bearing 4T1 cell tumors, 60 days for mice bearing MDA-MB-435 cell tumors
Result: Treatment resulted in a significant reduction in tumor volume.

分子量

717.62

Formula

C33H34N7Na2O7P
CAS 号

1144044-02-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解性数据
In Vitro: 

H2O : 62.5 mg/mL (87.09 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3935 mL 6.9675 mL 13.9350 mL
5 mM 0.2787 mL 1.3935 mL 2.7870 mL
10 mM 0.1393 mL 0.6967 mL 1.3935 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Jang GB, et al. Wnt/β-Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells. Cancer Res. 2015 Apr 15;75(8):1691-702.

    [2]. Kim JY, et al. Oncotarget. 2016 Apr 12;7(15):20395-409. CWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: a novel therapeutic approach for liver cancer treatment.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

DK419

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DK419  纯度: 99.68%

DK419 是一种有效、可口服的 Wnt/β-catenin 信号通路抑制剂，IC50 值为 0.19 μM。DK419 能降低 Axin2，β-catenin，c-Myc，Cyclin D1 和 Survivin 能够改变细胞内耗氧率，诱导 pAMPK 的产生。

DK419

DK419 Chemical Structure

CAS No. : 2102672-22-8

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥3850 In-stock
5 mg ￥3500 In-stock
10 mg ￥5500 In-stock
50 mg ￥16500 In-stock
100 mg ￥22500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

DK419 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK[1].

IC50 & Target

Wnt/β-catenin[1]
分子量

407.70

Formula

C16H8ClF6N3O
CAS 号

2102672-22-8
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 83.33 mg/mL (204.39 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.4528 mL 12.2639 mL 24.5278 mL
5 mM 0.4906 mL 2.4528 mL 4.9056 mL
10 mM 0.2453 mL 1.2264 mL 2.4528 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Wang J, et al. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth. Bioorg Med Chem. 2018 Nov 1;26(20):5435-5442.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NRX-252114

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NRX-252114 

NRX-252114 是一种有效的 β-catenin 与 同源 E3 ligase SCFβ-TrCP 的相互作用增强剂，增强 pSer33/S37A β-catenin 与 β-TrCP 的结合，EC50 为 6.5 nM，Kd 为 0.4 nM。NRX-252114 能够促进突变体 β-catenin 的降解。

NRX-252114

NRX-252114 Chemical Structure

CAS No. : 2763260-39-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation[1].

IC50 & Target

EC50: 6.5 nM (β-catenin:β-TrCP Interaction)[1]
Kd: 0.4 nM (β-catenin:β-TrCP Interaction)[1]
体外研究
(In Vitro)

NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with >1500-fold cooperativity, surpassing the affinity of wild-type doubly-phosphorylated peptide. NRX-252114 further enhances the ubiquitylation of pSer33/S37A β-catenin peptide to form long ubiquitin chains[1].
The non-phosphorylated Ser33/Ser37 peptide binds β-TrCP with very weak affinity (>100 μM); however, in the presence of 20 μM NRX-252114 that binding affinity is enhanced to 180 nM. NRX-252114 also potentiates the ubiquitylation of unphosphorylated Ser33/S37A β-catenin peptides by the SCFβ-TrCP complex[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

510.32

Formula

C22H12Cl2F3N3O2S
CAS 号

2763260-39-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kyle R Simonetta, et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat Commun. 2019 Mar 29;10(1):1402.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NRX-252114

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NRX-252114 

NRX-252114 是一种有效的 β-catenin 与 同源 E3 ligase SCFβ-TrCP 的相互作用增强剂，增强 pSer33/S37A β-catenin 与 β-TrCP 的结合，EC50 为 6.5 nM，Kd 为 0.4 nM。NRX-252114 能够促进突变体 β-catenin 的降解。

NRX-252114

NRX-252114 Chemical Structure

CAS No. : 2763260-39-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation[1].

IC50 & Target

EC50: 6.5 nM (β-catenin:β-TrCP Interaction)[1]
Kd: 0.4 nM (β-catenin:β-TrCP Interaction)[1]
体外研究
(In Vitro)

NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with >1500-fold cooperativity, surpassing the affinity of wild-type doubly-phosphorylated peptide. NRX-252114 further enhances the ubiquitylation of pSer33/S37A β-catenin peptide to form long ubiquitin chains[1].
The non-phosphorylated Ser33/Ser37 peptide binds β-TrCP with very weak affinity (>100 μM); however, in the presence of 20 μM NRX-252114 that binding affinity is enhanced to 180 nM. NRX-252114 also potentiates the ubiquitylation of unphosphorylated Ser33/S37A β-catenin peptides by the SCFβ-TrCP complex[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

510.32

Formula

C22H12Cl2F3N3O2S
CAS 号

2763260-39-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kyle R Simonetta, et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat Commun. 2019 Mar 29;10(1):1402.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NRX-252114

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NRX-252114 

NRX-252114 是一种有效的 β-catenin 与 同源 E3 ligase SCFβ-TrCP 的相互作用增强剂，增强 pSer33/S37A β-catenin 与 β-TrCP 的结合，EC50 为 6.5 nM，Kd 为 0.4 nM。NRX-252114 能够促进突变体 β-catenin 的降解。

NRX-252114

NRX-252114 Chemical Structure

CAS No. : 2763260-39-3

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

NRX-252114 is a potent enhancer of the interaction between β-catenin, and its cognate E3 ligase, SCFβ-TrCP. NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with an EC50 of 6.5 nM and a Kd of 0.4 nM. NRX-252114 induces mutant β-catenin degradation[1].

IC50 & Target

EC50: 6.5 nM (β-catenin:β-TrCP Interaction)[1]
Kd: 0.4 nM (β-catenin:β-TrCP Interaction)[1]
体外研究
(In Vitro)

NRX-252114 enhances the binding of pSer33/S37A β-catenin peptide for β-TrCP with >1500-fold cooperativity, surpassing the affinity of wild-type doubly-phosphorylated peptide. NRX-252114 further enhances the ubiquitylation of pSer33/S37A β-catenin peptide to form long ubiquitin chains[1].
The non-phosphorylated Ser33/Ser37 peptide binds β-TrCP with very weak affinity (>100 μM); however, in the presence of 20 μM NRX-252114 that binding affinity is enhanced to 180 nM. NRX-252114 also potentiates the ubiquitylation of unphosphorylated Ser33/S37A β-catenin peptides by the SCFβ-TrCP complex[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

510.32

Formula

C22H12Cl2F3N3O2S
CAS 号

2763260-39-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Kyle R Simonetta, et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nat Commun. 2019 Mar 29;10(1):1402.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

iCRT-5

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

iCRT-5 

iCRT-5 是一种 β-catenin 调节的转录 (CRT) 抑制剂。iCRT-5 可以阻断 Wnt/β-catenin 报告基因活性并下调 β-catenin 表达。iCRT-5 可用于多发性骨髓瘤的研究。

iCRT-5

iCRT-5 Chemical Structure

CAS No. : 18623-44-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma[1][2].

IC50 & Target

β-catenin-regulated transcription (CRT)[1]
分子量

367.44

Formula

C16H17NO5S2
CAS 号

18623-44-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124.

    [2]. Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32(11):4697-707.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

iCRT-5

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

iCRT-5 

iCRT-5 是一种 β-catenin 调节的转录 (CRT) 抑制剂。iCRT-5 可以阻断 Wnt/β-catenin 报告基因活性并下调 β-catenin 表达。iCRT-5 可用于多发性骨髓瘤的研究。

iCRT-5

iCRT-5 Chemical Structure

CAS No. : 18623-44-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma[1][2].

IC50 & Target

β-catenin-regulated transcription (CRT)[1]
分子量

367.44

Formula

C16H17NO5S2
CAS 号

18623-44-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124.

    [2]. Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32(11):4697-707.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

iCRT-5

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

iCRT-5 

iCRT-5 是一种 β-catenin 调节的转录 (CRT) 抑制剂。iCRT-5 可以阻断 Wnt/β-catenin 报告基因活性并下调 β-catenin 表达。iCRT-5 可用于多发性骨髓瘤的研究。

iCRT-5

iCRT-5 Chemical Structure

CAS No. : 18623-44-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

iCRT-5 is a β-catenin-regulated transcription (CRT) inhibitor. iCRT-5 can block Wnt/β-catenin reporter activity and down regulate β-catenin expression. iCRT-5 can be used for the research of multiple myeloma[1][2].

IC50 & Target

β-catenin-regulated transcription (CRT)[1]
分子量

367.44

Formula

C16H17NO5S2
CAS 号

18623-44-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124.

    [2]. Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32(11):4697-707.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

β-catenin peptide

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

β-catenin peptide 

β-catenin peptide 一种 八肽，可以促进胸腺细胞阳性选择 [1] 。

β-catenin peptide

β-catenin peptide Chemical Structure

CAS No. : 265669-37-2

规格 价格 是否有货
1 mg ￥1200 询问价格 & 货期
5 mg ￥3900 询问价格 & 货期
10 mg ￥6100 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

β-catenin peptide is a 8-aa peptide, and can promote thymocyte positive selection.

体外研究
(In Vitro)

β-catenin peptide is a 8-aa peptide of β-catenin, and can promote thymocyte positive selection[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

1073.20

Formula

C49H76N12O15
CAS 号

265669-37-2
Sequence

Arg-Thr-Tyr-Thr-Tyr-Glu-Lys-Leu
Sequence Shortening

RTYTYEKL
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro: 

H2O

Peptide Solubility and Storage Guidelines:

1.  Calculate the length of the peptide.

2.  Calculate the overall charge of the entire peptide according to the following table:

  Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.  Recommended solution:

Overall charge of peptide Details
Negative (<0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, add NH4OH (<50 μL).
3.  If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0) 1.  Try to dissolve the peptide in water first.
2.  If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.  If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.  Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.  For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Santori FR, et al. Rare, structurally homologous self-peptides promote thymocyte positive selection. Immunity. 2002 Aug;17(2):131-42.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

ICG-001

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ICG-001  纯度: 99.83%

ICG-001 是 β-catenin/TCF 介导的转录抑制剂。 ICG-001 特异性结合 CREB 蛋白起作用，IC50 为3 μM。ICG-001 选择性地阻断 β-catenin/CBP 相互作用而不干扰 β-catenin/p300 相互作用。

ICG-001

ICG-001 Chemical Structure

CAS No. : 780757-88-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1112 In-stock
5 mg ￥921 In-stock
10 mg ￥1200 In-stock
50 mg ￥4500 In-stock
100 mg ￥8184 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

ICG-001 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.

IC50 & Target

IC50: 3 μM (CBP)
体外研究
(In Vitro)

ICG-001 (5μM) inhibits leptin-induced EMT, invasion and tumorsphere formation in MCF7 cells[1]. ICG-001 can phenotypically rescue normal nerve growth factor (NGF)-induced neuronal differentiation and neurite outgrowth in the presenilin-1 mutant cells, emphasizing the importance of the TCF/β-catenin signaling pathway on neurite outgrowth and neuronal differentiation[2]. ICG-001 (25μM) treatment reduces the steady-state levels of Survivin and Cyclin D1 RNA and protein in SW480 cells, both of which can be up-regulated by β-catenin. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, and reduces in vitro growth of colon carcinoma cells[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

ICG-001 (5 mg/kg per day) significantly inhibits beta-catenin signaling in mice, while concurrently preserving the epithelium[2]. Administration of a water-soluble analog of ICG-001 for 9 weeks reduces the formation of colon and small intestinal polyps by 42% as effectively as the nonsteroidal antiinflammatory agent MK-231, which has consistently demonstrated efficacy in this model. ICG-001 (150 mg/kg, i.v.) demonstrates a dramatic reduction in tumor volume over the 19-day course of treatment, with no mortality or weight loss in the SW620 nude mouse xenograft model of tumor regression[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

548.63

Formula

C33H32N4O4
CAS 号

780757-88-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 50 mg/mL (91.14 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8227 mL 9.1136 mL 18.2272 mL
5 mM 0.3645 mL 1.8227 mL 3.6454 mL
10 mM 0.1823 mL 0.9114 mL 1.8227 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.56 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.56 mM); Suspended solution; Need ultrasonic and warming

    此方案可获得 2.5 mg/mL (4.56 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.56 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Yan D, et al, Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem, 2012, 287(11), 8598-8612.

    [2]. Henderson WR Jr, et al, Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA, 2010, 107(32), 14309-14314.

    [3]. Emami KH, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA, 2004, 101(34), 12682-12687.

    [4]. Liu Y, et al. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 2017 Sep 11;36(1):125.
Cell Assay
[2]

To evaluate effects of ICG-001 on α-SMA and collagen type 1 expression, RLE-6TN cells are treated with TGF-β1 (0.25 ng/mL) in the presence or absence of ICG-001 (5.0 μM). After 24 h, cells are harvested and mRNA isolated for analysis by qPCR. RNA is reverse-transcribed using SuperScript reverse transcriptase. Quantitative PCR is performed with SYBR-Green PCR using Real-Time PCR System HT7900. The amplification protocol is set as follows: 95°C denaturation for 10 min followed by 40 cycles of 15-s denaturation at 95°C, 1 min of annealing/extension, and data collection at 60°C.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[3]

Seven-week-old male C57BL/6J-ApcMin/+and WT C57BL/6J mice are treated orally for 9 weeks with ICG-001a (300 mg/kg per day) or vehicle (1% carboxymethylcellulose), once daily, six times per week. MK-231 is administered in drinking water (160 ppm, dissolved in 8 mM Na2PO4 buffer, pH 7.6). At 16 weeks, the polyp number is counted manually by using a dissecting microscope.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Yan D, et al, Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem, 2012, 287(11), 8598-8612.

    [2]. Henderson WR Jr, et al, Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci USA, 2010, 107(32), 14309-14314.

    [3]. Emami KH, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci USA, 2004, 101(34), 12682-12687.

    [4]. Liu Y, et al. ICG-001 suppresses growth of gastric cancer cells and reduces chemoresistance of cancer stem cell-like population. J Exp Clin Cancer Res. 2017 Sep 11;36(1):125.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

SKL2001

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SKL2001  纯度: 99.54%

SKL2001 是 Wnt/β-catenin 信号通路的激动剂，具有抗肿瘤活性。SKL2001 通过破坏 Axin/β-catenin 相互作用，稳定细胞内 β-catenin。

SKL2001

SKL2001 Chemical Structure

CAS No. : 909089-13-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥770 In-stock
10 mg ￥700 In-stock
50 mg ￥2900 In-stock
100 mg ￥5200 In-stock
200 mg ￥8200 In-stock
500 mg   询价  
1 g   询价  

* Please select Quantity before adding items.

SKL2001 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Reprogramming Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library

生物活性

SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction[1].

IC50 & Target

Wnt/β-catenin[1]
体外研究
(In Vitro)

SKL2001 is an agonist of the Wnt/β-catenin pathway, and also upregulates the expression of Axin2, a downstream target of the Wnt/β-catenin pathway, but shows no effect on NF-κB, p53 reporter activity and GSK-3β activity. SKL2001 causes osteoblast differentiation (20 and 40 μM) and suppresses preadipocyte differentiation (5, 10, and 30 μM) via the activation of the Wnt/β-catenin pathway. SKL2001 (5, 10, and 30 μM) stabilizes intracellular β-catenin in 3T3-L1 cells[1]. SKL2001 (40 μM) significantly inhibits the proliferation of HCT116 spheroids independently of cytotoxicity and the inhibition is reversible; SKL2001 cuases cell cycle arrest in HCT116 spheroids. SKL2001 (40 μM) enhances round-shape spheroid formation and E-cadherin expression[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

286.29

Formula

C14H14N4O3
CAS 号

909089-13-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 96.66 mg/mL (337.63 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.4930 mL 17.4648 mL 34.9296 mL
5 mM 0.6986 mL 3.4930 mL 6.9859 mL
10 mM 0.3493 mL 1.7465 mL 3.4930 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.73 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (8.73 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (8.73 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Gwak J, et al. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation. ell Res. 2012 Jan;22(1):237-47.

    [2]. Ohashi W, et al. SKL2001 suppresses colon cancer spheroid growth through regulation of the E-cadherin/β-Catenin complex. Biochem Biophys Res Commun. 2017 Nov 25;493(3):1342-1348.
Cell Assay
[1]

ST2 cells are cultured on glass chamber slides and then treated with DMSO or SKL2001 for 15 h. After treatment, the cells are washed with PBS, fixed with 4% formaldehyde, permeabilized in 0.3% Triton X-100, and blocked in 4% bovine serum albumin for 1 h. The cells are stained with anti-β-catenin antibody and then analyzed by confocal microscopy using a microscope[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Gwak J, et al. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation. ell Res. 2012 Jan;22(1):237-47.

    [2]. Ohashi W, et al. SKL2001 suppresses colon cancer spheroid growth through regulation of the E-cadherin/β-Catenin complex. Biochem Biophys Res Commun. 2017 Nov 25;493(3):1342-1348.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

NRX-252262

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

NRX-252262  纯度: 98.97%

NRX-252262 是一种有效的 β-Catenin 与 同源 E3 ligase SCFβ-TrCP 的相互作用增强剂，能够促进 β-catenin 的降解，EC50 值为 3.8 nM。

NRX-252262

NRX-252262 Chemical Structure

CAS No. : 2438637-61-5

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4199 In-stock
1 mg ￥1800 In-stock
5 mg ￥3500 In-stock
10 mg ￥5500 In-stock
25 mg ￥9900 In-stock
50 mg ￥16500 In-stock
100 mg ￥22500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

NRX-252262 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

NRX-252262 is a potent enhancer of the interaction between β-Catenin, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM[1].

IC50 & Target

EC50: 3.8 nM (β-Catenin-SCFβ-TrCP)[1]
体外研究
(In Vitro)

NRX-252262 (35 μM) causes S33E/S37A mutant β-catenin degradation in cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

545.36

Formula

C23H17Cl2F3N2O4S
CAS 号

2438637-61-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 8.33 mg/mL (15.27 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8337 mL 9.1683 mL 18.3365 mL
5 mM 0.3667 mL 1.8337 mL 3.6673 mL
10 mM 0.1834 mL 0.9168 mL 1.8337 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Kyle R. Simonetta, et al. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction. Nature Communications. 2019 March.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

MSAB

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MSAB  纯度: 99.77%

MSAB 是 Wnt/β-catenin 信号传导的有效和选择性抑制剂。MSAB 与 β-catenin 结合，促进其降解，并特别下调 Wnt/β-catenin 靶基因。MSAB 对 Wnt 依赖性癌细胞显示出有效的抗肿瘤作用。

MSAB

MSAB Chemical Structure

CAS No. : 173436-66-3

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥940 In-stock
5 mg ￥850 In-stock
10 mg ￥1500 In-stock
25 mg ￥3000 In-stock
50 mg ￥4500 In-stock
100 mg ￥6800 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

MSAB 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Cytoskeleton Compound Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells[1].

IC50 & Target

Wnt/β-catenin[1]
体外研究
(In Vitro)

MSAB (2-10 μM) selectively decreases cell viability of Wnt-dependent cells while showing little effect on Wnt-independent cells and normal human cells[1].
MSAB (0.01-10 μM; 20 h) inhibits T-cell factor (TCF) luciferase reporter activity in HCT116 cells[1].
MSAB (20 h) suppresses the Wnt3a-induced TOP-Luc activation and increases of active β-catenin levels in HEK293T cells[1].
MSAB (0.5-10 μM; 20 h) decreases mRNA and protein levels of endogenous Wnt target genes in HCT116 cells[1].
MSAB (5 μM; 16 h) induces degradation of β-catenin in a proteasome-dependent manner in HCT116 cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

MSAB (10-20 mg/kg; i.p. daily for 2 weeks) inhibits tumor growth of Wnt-dependent cancer cells in mouse xenograft model[1].
MSAB (10-20 mg/kg; i.p. twice daily for 2 weeks) inhibits tumor growth of MMTV-Wnt1 transgenic mice[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Athymic nude mice (5-6 weeks) are injected HCT116, HT115, H23, or H460 cells[1]
Dosage: 10, 20 mg/kg
Administration: I.p. daily for 2 weeks
Result: Reduced the size and weight of various types of Wnt-dependent HCT116, HT115, and H23 tumors.

分子量

305.35

Formula

C15H15NO4S
CAS 号

173436-66-3
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 250 mg/mL (818.73 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2749 mL 16.3747 mL 32.7493 mL
5 mM 0.6550 mL 3.2749 mL 6.5499 mL
10 mM 0.3275 mL 1.6375 mL 3.2749 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (6.81 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.81 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (6.81 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.81 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Hwang SY, et, al. Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Rep. 2016 Jun 28;16(1):28-36.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Wnt/β-catenin agonist 1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Wnt/β-catenin agonist 1 

Wnt/β-catenin agonist 1 (compound 3f) 是 Wnt/β-catenin 信号通路的一个激动剂，EC50 值为 0.27 μM。

Wnt/β-catenin agonist 1

Wnt/β-catenin agonist 1 Chemical Structure

CAS No. : 2305372-67-0

规格 价格 是否有货
5 mg ￥4500 询问价格 & 货期
10 mg ￥7200 询问价格 & 货期
25 mg ￥14600 询问价格 & 货期

* Please select Quantity before adding items.

生物活性

Wnt/β-catenin agonist 1 (compound 3f) is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM[1].

体外研究
(In Vitro)

EC50: 0.27 μM (Wnt/β-catenin)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

363.45

Formula

C22H25N3O2
CAS 号

2305372-67-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chen DZ, et al. Design, synthesis and structure-activity relationship optimization of phenanthridine derivatives as new Wnt/β-catenin signalling pathway agonists. Bioorg Chem. 2019 Mar;84:285-294.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

大鼠β-连环蛋白（β-catenin）ELISA试剂盒BS-3660

发表于由

大鼠β-连环蛋白（β-catenin）ELISA试剂盒

  • 产品型号：BS-3660
  • 简要描述：大鼠β-连环蛋白（β-catenin）ELISA试剂盒金畔生物公司供应：ELISA试剂盒,荧光定量PCR耗材，移液器吸嘴，微量离心管，进口冻存管，细胞培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。
产品咨询在线客服
  • 产品简介

大鼠β-连环蛋白(β-catenin)ELISA试剂盒金畔生物公司供应：ELISA试剂盒,血清，荧光定量PCR耗材，移液器吸嘴，微量离心管，进口冻存管，细胞培养皿，培养板，培养瓶，吸头，仪器及手套，色谱耗材，针头过滤器。

货号：BS-3660

规格：96T/48T

产品名：大鼠β-连环蛋白(β-catenin)ELISA试剂盒

检测种属：人、大小鼠、豚鼠、兔子、猪、犬、牛羊、鸡鸭、猴ELISA试剂盒等种属。

保存条件及有效期：

1、试剂盒保存：2-8℃。

2、有效期：6个月

标记物：血清、血浆、组织匀浆等

【测试种属】犬、大小鼠、人、豚鼠、兔子、牛羊、猪、鸡鸭elisa试剂盒等种属
【储存方式】：2-8℃
【检测目的】用于测定血清，血浆及相关液体等样本。例如适合检测包括血清、血浆、尿液、胸腹水、灌洗液、脑脊液、细胞培养上清、组织匀浆等标本。
【用途】科研实验，不用于临床诊断。

大鼠ELISA试剂盒  大鼠ELISAkit   试剂盒代测   β-连环蛋白(β-catenin)

大鼠β-连环蛋白(β-catenin)ELISA检测试剂盒影响ELISA试剂盒实验的因素
一、试剂盒
1、抗原、抗体活性对效价的影响：主要是试剂中抗体(或抗原)的效价降低或失活，结果不易判断。再有ELISA法灵敏度高，对杂质的反应灵敏度也高，实验中空白对照OD值偏高或假阳性;
2、酶结合物浓度过高，也会导致OD值假性增高。
二、试验仪器
1、ELISA试剂盒加样器是否经过校正，酶免测定血清用血量很少，如手工加样器的性能不好，吸取样品不，会使结果忽高忽低;
2、每次洗板前，应检查洗板机针孔有无堵塞。
三、操作
1、检测前先将试剂盒从冰箱取出置室温平衡20min后使用，试剂用完及时放回冰箱冷藏，以免造成试验结果假性降低;
2、加样时注意勿触及包被板底部，以免擦伤包被物使抗体(抗原)脱落而影响实验结果的准确性;
3、洗涤不充分，会使结果假性增高，过分洗涤呈假阴性;
4、比色时应保持包被孔底部无异物、无水汽，特别是冬季板从37℃水浴箱取出时，底部留有水汽，应将板底擦干后进行比色，水汽或孔内气泡也会使OD值升高;
5、抗原与抗体反应达到*平衡，依赖于温度与时间。温度高于45℃易引起失活及标记物脱落，温度低于4℃，影响反应速度。

操作步骤：

大鼠β-连环蛋白（β-catenin）ELISA试剂盒BS-3660

大鼠β-连环蛋白(β-catenin)ELISA检测试剂盒组成：
试剂盒组成48 孔配置96 孔配置保存
说明书1 份1 份
封板膜2 片(48)2 片(96)
密封袋1 个1 个
酶标包被板1×481×962-8℃保存
标准品：540μg/L0.5ml×1 瓶0.5ml×1 瓶2-8℃保存
标准品稀释液1.5ml×1 瓶1.5ml×1 瓶2-8℃保存
酶标试剂3 ml×1 瓶6 ml×1 瓶2-8℃保存
样品稀释液3 ml×1 瓶6 ml×1 瓶2-8℃保存
显色剂 A 液3 ml×1 瓶6 ml×1 瓶2-8℃保存
显色剂 B 液3 ml×1 瓶6 ml×1 瓶2-8℃保存
终止液3 ml×1 瓶6 ml×1 瓶2-8℃保存
浓缩洗涤液(20ml×20 倍)×1 瓶(20ml×30 倍)×1 瓶2-8℃保存

BS-3661大鼠癌胚抗原(CEA)ELISA试剂盒

BS-3662大鼠低密度脂蛋白胆固醇(LDL-C)ELISA试剂盒

BS-3664大鼠核因子κB受体活化因子(Rank)ELISA试剂盒

BS-3665大鼠基质金属蛋白酶-9(MMP-9)ELISA试剂盒

BS-3666大鼠精氨酸加压素(AVP)ELISA试剂盒

BS-3667大鼠类风湿因子(RF)ELISA试剂盒

BS-3669大鼠卵白蛋白特异性IgE(OVA-sIgE)ELISA试剂盒

BS-3670大鼠凝血因子Ⅷ(FⅧ)ELISA试剂盒

BS-3671大鼠神经激肽B(NKB)ELISA试剂盒

BS-3674大鼠乙酰胆碱酯酶(AchE)ELISA试剂盒

BS-3675大鼠白细胞介素-1受体(IL-1R)ELISA试剂盒

BS-3676大鼠促黄体生成素(LH)ELISA试剂盒

BS-3677大鼠淀粉酶(AMS)ELISA试剂盒

10ml 自立试管,PP无DNA酶/RNA酶无热源无菌

上海15ml离心管/10/50ml锥底圆底管无酶

1-200ul, 0.57mm 凝胶加样吸嘴, 无色, 盒装灭菌

1-200ul, 0.57mm 凝胶加样吸嘴, 无色, 袋装非灭菌

Tip 1-200ul, 黄色，BASIX短吸嘴，袋装非灭菌

Tip 1-200ul,黄色短吸嘴,袋装

适配伯乐CFX96仪用PCR板/全裙边40ul96孔板

人N钙黏蛋白/神经钙黏蛋白(N-Cad)ELISA试剂盒

人肝素结合性表皮生长因子(HB-EGF)ELISA试剂盒

人红细胞刺激因子(ESF)ELISA试剂盒

人基质裂解素(ST1)ELISA试剂盒

人基质裂解素(ST2)ELISA试剂盒

人基质裂解素(ST3)ELISA试剂盒

人破骨细胞分化因子(ODF)ELISA试剂盒

人肿瘤坏死因子相关激活诱导因子(TRANCE)ELISA试剂盒

人生长激素释放因子(GH-RF)ELISA试剂盒

人α/β干扰素受体(IFN-α/βR)ELISA试剂盒

 

产品用途：可用于科研实验,不用于临床治疗！

ZW4864

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ZW4864 

ZW4864 是一种具有口服活性和选择性的 β catenin/ B-Cell lymphoma 9 蛋白-蛋白相互作用 (β catenin/BCL9 PPI) 抑制剂。ZW4864 抑制 β catenin/BCL9 PPI 的 Ki 值为0.76 μM，IC50 值为 0.87 μM。

ZW4864

ZW4864 Chemical Structure

CAS No. : 2632259-93-7

规格 价格 是否有货
5 mg ￥5000 询问价格 & 货期
10 mg ￥8500 询问价格 & 货期

* Please select Quantity before adding items.

ZW4864 的其他形式现货产品:

ZW4864 free base

生物活性

ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein−protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM[1].

IC50 & Target

IC50: 0.87 μM (β catenin/BCL9 PPI)[1].
Ki: 0.76 μM(β catenin/BCL9 PPI)[1]
体外研究
(In Vitro)

ZW4864 (10~40 μM; 24 hours; SW480 and MBA-MD-231 cells) decreases the expression levels of Axin2 and cyclin D1 proteins[1].
ZW4864 (10~40 μM; 72 hours; MDA-MB231, MCF10A and MDA-MB-468 cells) selectively triggeres rapid apoptosis of triple-negative breast cancer cells with hyperactive β-catenin signaling while sparing normal mammary epithelial MCF10A cells[1].
ZW4864 (10~40 μM; 24 hours; SW480 and MBA-MD-231 cells) suppresses the transcription of β-catenin target genes in a concentration-dependent manner without affecting the expression of HPRT, a house-keeper gene, in both SW480 and Wnt 3a-activated MDA-MB-231 cells[1].
ZW4864 binds with β-catenin and selectively disrupts the protein−protein interaction (PPI) between B-cell lymphoma 9 (BCL9) and β-catenin while sparing the β-catenin/E-cadherin PPI. ZW4864 dose-dependently suppresses β-catenin signaling activation, downregulates oncogenic β-catenin target genes, and abrogates invasiveness of β-catenin-dependent cancer cells. ZW4864 suppresses TOPFlash luciferase activities in β-catenin expressing HEK293 cells in a dose-dependent manner with an IC50 of 11 μM. ZW4864 also dose-dependently suppresses the TOPFlash luciferase activities in SW480 and Wnt 3a-activated MDA-MB-468 cells with the IC50s of 7.0 and 6.3 μM, respectively. ZW4864 selectively suppresses transactivation of β-catenin signaling[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: SW480 and MBA-MD-231 cells
Concentration: 10~40 μM
Incubation Time: 24 hours
Result: Decreased the expression levels of Axin2 and cyclin D1 proteins.

Apoptosis Analysis[1]

Cell Line: MDA-MB231, MCF10A and MDA-MB-468 cells
Concentration: 10~40 μM
Incubation Time: 72 hours
Result: Selectively triggered rapid apoptosis of triple-negative breast cancer cells with hyperactive β-catenin signaling while sparing normal mammary epithelial MCF10A cells.

RT-PCR[1]

Cell Line: SW480 and MBA-MD-231 cells
Concentration: 10~40 μM
Incubation Time: 24 hours
Result: Suppressed the transcription of β-catenin target genes in a concentration-dependent manner without affecting the expression of HPRT, a house-keeper gene, in both SW480 and Wnt 3a-activated MDA-MB-231 cells.

体内研究
(In Vivo)

ZW4864 (20 mg/kg; p.o.) exhibits good pharmacokinetic properties with an oral bioavailability (F) of 83 %[1].
ZW4864 (90 mg/kg; p.o.) shows a variation in tumor growth in mice[1].
ZW4864 shows good pharmacokinetic properties and effectively suppresses β-catenin target gene expression in the patient-derived xenograft mouse model[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice[1]
Dosage: 20 mg/kg (Pharmacokinetic Analysis)
Administration: P.o.
Result: Exhibited good pharmacokinetic properties with an oral bioavailability (F) of 83%.
Animal Model: Mice[1]
Dosage: 90 mg/kg
Administration: P.o.
Result: Showed a variation in tumor growth in mice.

分子量

607.19

Formula

C33H43ClN6O3
CAS 号

2632259-93-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
溶解性数据
In Vitro: 

DMSO : 41.67 mg/mL (68.63 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6469 mL 8.2347 mL 16.4693 mL
5 mM 0.3294 mL 1.6469 mL 3.2939 mL
10 mM 0.1647 mL 0.8235 mL 1.6469 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.43 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.43 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.43 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.43 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Wang Z, et al. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. J Med Chem. 2021;64(16):12109-12131.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务